N-Methyl-2,3-dimethylbenzylamine | 110931-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Methyl-2,3-dimethylbenzylamine
• 英文别名: (2,3-dimethylbenzyl)methylamine；1-(2,3-dimethylphenyl)-N-methylmethanamine
• CAS: 110931-75-4
• 化学式: C₁₀H₁₅N
• mdl: MFCD11104073
• 分子量: 149.236
• InChiKey: GTLDXGZOKFSBMF-UHFFFAOYSA-N

物化性质

• 沸点：
  222.5±9.0 °C(Predicted)
• 密度：
  0.912±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Methyl-2,3-dimethylbenzylamine 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 19.5h， 生成 2-[(2,3-Dimethylphenyl)methyl-methylamino]-1-phenylethanol
  参考文献：
  名称：

  4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

  摘要：

  Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.050
• 作为产物：
  描述：

  1-(2,3-dimethylphenyl)-N-methylmethanimine 在 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 反应 2.5h， 生成 N-Methyl-2,3-dimethylbenzylamine
  参考文献：
  名称：

  4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

  摘要：

  Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.050

文献信息

• [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY<br/>[FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT
  申请人：AFFINIUM PHARM INC

  公开号：WO2004052890A1

  公开（公告）日：2004-06-24

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。
• INDAZOLEPROPIONIC ACID AMIDE COMPOUND
  申请人：Yamaguchi Tetsuo

  公开号：US20120016117A1

  公开（公告）日：2012-01-19

  Disclosed is a compound which is useful in preventing and treating cardiac arrhythmia such as atrial fibrillation. A compound represented by formula (1) or a pharmaceutically acceptable salt of the same. In formula (1), ring X represents benzene or pyridine; R 1 represents an optionally substituted alkyl group; R 2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted arylalkyl group or an optionally substituted heterocyclic group-substituted alkyl group; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent each hydrogen or an alkyl group, provided that R 3 and R 5 may be bonded to each other to form, together with the carbon atom adjacent thereto, a cycloalkyl group; and m represents 0 or 1.

  本申请揭示了一种化合物，用于预防和治疗心律失常，如心房纤颤。该化合物由式（1）表示，或者其药学上可接受的盐。在式（1）中，环X代表苯或吡啶；R1代表可选择地取代的烷基基团；R2代表可选择地取代的芳基基团，可选择地取代的杂环基团，可选择地取代的芳基烷基基团或可选择地取代的杂环基团取代的烷基基团；R3、R4、R5、R6、R7、R8和R9分别代表氢或烷基基团，但R3和R5可以结合在一起，与相邻的碳原子一起形成环烷基基团；m代表0或1。
• THYROID RECEPTOR LIGANDS
  申请人：Ryono Denis E.

  公开号：US20100298276A1

  公开（公告）日：2010-11-25

  Thyroid receptor ligands are provided which have the general formula I wherein: R 1 is R 2 and R 3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R 2 and R 3 is other than hydrogen; R 4 is R 5 and R 6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R 7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R 8 is aryl, heteroaryl, or cycloalkyl; R 9 is R 7 or hydrogen; R 10 is hydrogen, halogen, cyano or alkyl; R 11 and R 12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R 13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R 14 and R 15 may be the same or different and are selected from hydrogen and alkyl, or R 14 and R 15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R 16 is hydrogen or alkyl of 1 to 4 carbons; R 17 and R 18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO 2 —), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

  提供了甲状腺受体配体，其具有一般公式I，其中：R1为R2和R3，R2和R3相同或不同，为氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，但至少其中一个为非氢；R4为R5和R6，R5和R6相同或不同，选择自氢、芳基、杂环芳基、烷基、环烷基、芳基烷基或杂环芳基；R7为芳基、杂环芳基、烷基、芳基烷基或杂环芳基；R8为芳基、杂环芳基或环烷基；R9为R7或氢；R10为氢、卤素、氰基或烷基；R11和R12各自独立选择自氢、卤素、烷氧基、羟基（—OH）、氰基和烷基；R13为羧酸（COOH）或其酯、膦酸和膦酸酯、磺酸、四唑、羟胺酸、噻唑二酮、酰基磺胺或艺术中已知的其他羧酸替代物；R14和R15可相同或不同，选择自氢和烷基，或R14和R15可结合形成2至5个亚甲基组成的链[—(CH2)m-，m=2、3、4或5]，从而形成3至6成员的环烷基环；R16为氢或1至4个碳原子的烷基；R17和R18相同或不同，选择自氢、卤素和烷基；n为0或1至4的整数；X为氧（—O—）、硫（—S—）、砜基（—SO2—）、砜基（—SO—）、硒（—Se—）、羰基（—CO—）、氨基（—NH—）或亚甲基（—CH2-）；其中取代基如上述所述。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或障碍，其中上述化合物以治疗有效剂量给予。
• [EN] TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR1-ANTICORPS ANTI-ASGR ET UTILISATIONS ASSOCIÉES
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021072203A1

  公开（公告）日：2021-04-15

  Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.

  本发明揭示了用于治疗肝病（如肝癌和肝纤维化）的各种共轭物和其组合物。这些组合物包括共轭物，其中共轭物由特异于ASGR1或ASGR2的抗体或抗体构造物通过连接剂连接到TGFβR1抑制剂上。此外，还提供了这些共轭物和组合物的制备方法。
• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021011834A1

  公开（公告）日：2021-01-21

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。所披露的化合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。此外，本文还描述了与抗体构造物结合的化合物。